Bremelanotide, also known as PT-141, is a synthetic cyclic heptapeptide derived from Melanotan II (MT-II), a synthetic analog of the melanocortin hormone α-melanocyte-stimulating hormone (α-MSH).^[1][2] It was initially investigated for its potential role in addressing hypoactive sexual desire disorder (HSDD) in female research models, as evaluated in Phase IIb clinical trials by qualified researchers. Research has also explored its potential applications in managing acute hemorrhage, suggesting broader physiological interactions beyond its primary area of study.

 

Mechanism of Action

The biological activity of Bremelanotide is hypothesized to be mediated through its selective agonism of melanocortin receptors, particularly MC3R and MC4R.^[3] MC3R is predominantly expressed in the hypothalamus and has been linked to energy homeostasis, metabolic regulation, and neuroendocrine modulation. Research suggests that MC3R activity may impact feeding behavior, glucose metabolism, and lipid balance, though the precise regulatory mechanisms remain under investigation.

Conversely, MC4R is believed to play a critical role in suppressing hunger hormone signaling and regulating energy expenditure. Preclinical data suggest that its activation within the CNS may contribute to neurogenic control of metabolic functions, potentially impacting the regulation of adipose stores. In addition, MC4R has been proposed to have a role in reproductive signaling. Receptor activation is often hypothesized to impact neuroendocrine pathways linked to reproductive physiology.

Preliminary studies suggest that Bremelanotide’s binding to MC3R and MC4R may lead to neuronal activation in the hypothalamus. This may potentially trigger downstream signaling cascades associated with autonomic and neuroendocrine responses. Laboratory studies of murine research models suggest that this interaction may contribute to behavioral responses related to copulatory arousal. However, further research is necessary to elucidate the exact mechanisms underlying these findings.

 

Scientific Research and Studies

 

Early Investigations of Bremelanotide Peptide

An early 2000s study^[4] investigated the potential neuropharmacological impacts of Bremelanotide in murine models, focusing on its possible role in modulating mating behavior. The study involved observing female murine models to study behavioral responses following peptide exposure.

Observations suggested that while research models exhibited increased solicitation related to mating behavior, there were no notable alterations in motor activity, lumbar lordosis, or other mating-related behaviors. Based on these findings, researchers hypothesized that Bremelanotide does not act as a general motor stimulant but may potentially exert selective pharmacological impacts on the central nervous system (CNS), particularly through melanocortin receptor activation. The study further suggested that central melanocortin pathways might be integral to neurochemical mechanisms underlying copulation-related arousal.

Researchers further noted the stability and selectivity of this response across varied experimental conditions, citing, “The ability of PT-141 to enhance solicitation in two distinctive testing environments indicates that the effect [appears] selective and stable, and suggests that central melanocortin systems are part of the neurochemical network that evokes appetitive sexual behavior in female rats.” These findings provided preliminary data that suggests the role of melanocortin receptors in modulating copulatory motivation may warrant further investigation into the underlying neuroendocrine mechanisms.

 

Neurophysiological Interactions of Bremelanotide in the Central Nervous System

Studies on the Bremelanotide peptide have focused on its potential interactions within the central nervous system (CNS), particularly in brain regions implicated in neuroendocrine and behavioral responses. Preclinical studies utilizing murine models with elevated levels of reproductive hormones have reportedly displayed behavioral modifications following peptide introduction. According to reports, these studies have primarily assessed appetitive behaviors, such as increased locomotion and solicitation, alongside consummatory responses, including lordosis.

Experimental findings suggest that Bremelanotide exposure may be associated with heightened hunger-related behaviors without significantly altering consummatory responses. These studies report that the peptide’s impacts were observed following both peripheral and direct introduction into the lateral ventricles or the medial preoptic area (mPOA) but not the ventromedial hypothalamus. The mPOA has been implicated in modulating the drive toward mating behaviors across various species, though its precise role remains under investigation. Bremelanotide’s interaction with this region, as well as other hypothalamic and limbic structures, suggests potential involvement in neural pathways associated with behavioral modulation. It has been hypothesized that Bremelanotide may exert its impacts through the activation of dopamine terminals within the mPOA, though further research is required to validate this hypothesis.^[5]

To further elucidate these mechanisms, a randomized, double-blinded, placebo-controlled crossover study^[6] incorporated psychometric assessments, functional neuroimaging, and hormonal analyses to examine the impact of MC4R agonism on neural processing. Results suggested that MC4R agonists, including Bremelanotide, might support an increase in copulatory motivation for up to 24 hours relative to placebo controls. Functional neuroimaging analyses suggested increased activation in the cerebellar and supplementary motor regions, alongside possible deactivation of the secondary somatosensory cortex when exposed to erotic stimuli. Additionally, MC4R agonism was associated with heightened functional connectivity between the amygdala and insular cortex under similar conditions. These findings suggest a potential role of melanocortin receptor modulation in neural circuits governing behavioral and neuroendocrine responses. Further studies are warranted to delineate the precise neurophysiological mechanisms underlying these observations.

 

Melanocortin Receptor Activation and Cavernosal Response

Bremelanotide has been hypothesized to activate melanocortin 4 receptors (MC4R) and modulate vasodilatory pathways, potentially influencing erectile function in male animal models.

Research^[7] suggests that this activation may upregulate the production of nitric oxide (NO) within penile tissues, which may ultimately contribute to increased cavernosal pressure. Bremelanotide, a synthetic derivative of Melanotan-II (MT-II), shares a similar receptor affinity profile, with both peptides exhibiting agonistic properties toward melanocortin receptors.

Experimental findings suggest that melanocortin agonists might induce dose-dependent elevations in cavernosal pressure. The non-selective MC3R and MC4R antagonist SHU 9119 did not appear to directly impact systemic or cavernosal blood pressure; however, it seemingly inhibited the cavernosal pressure increases induced by melanocortin agonists. Additionally, SHU 9119 was reported to suppress the depressor response potentially associated with melanocortin activation.

Further studies investigated the role of the NO-cyclic GMP-dependent pathway in melanocortin-mediated cavernosal responses. When a pharmacological combination of phentolamine mesylate, papaverine, and prostaglandin E1 (PGE1) was locally introduced to cavernosal tissue, cavernosal pressure reportedly increased fourfold. The involvement of neuronal NO release was examined through bilateral pudendal nerve transection and inhibition of NO synthase via L-NAME. These interventions appeared to negate the cavernosal pressure increases observed with melanocortin agonists, suggesting that central melanocortin receptor activation might influence penile tissue responses through NO-mediated neural pathways.

These findings provide preliminary insights into the potential physiological interactions between melanocortin receptor activation and neurovascular regulation, though further research is necessary to elucidate the precise mechanisms involved.

 

Bremelanotide Peptide and Hemorrhagic Shock

In 2009, a modified form of Bremelanotide was explored for its potential role in mitigating hemorrhagic shock. As an agonist of both melanocortin 1 receptor (MC1R) and melanocortin 4 receptor (MC4R), the peptide has been hypothesized to exert protective impacts against ischemic injury by supporting tissue resilience under conditions of reduced blood perfusion.

Preclinical investigations suggest that its receptor interactions may contribute to vascular stability and modulate systemic responses to hypovolemia. To further assess its viability in this context, a structurally altered analog, PL-6983, was developed and advanced to Phase IIb clinical trials.

 

Bremelanotide Peptide and Infectious Disease

Research on melanocortin receptors (MC1R) suggests that they may modulate immune responses, particularly in fungal infections. In experimental murine models, MC1R activation has been associated with antifungal and anti-inflammatory properties^[9], suggesting a possible role in host defense mechanisms. Given the limitations of conventional antifungal research tools, many of which exhibit restrictive mechanisms of action and significant adverse impacts, MC1R-targeting compounds may offer an alternative strategy for infection management. This might prove particularly relevant for immunocompromised individuals, where fungal infections pose substantial morbidity and mortality risks.

 

Bremelanotide Peptide and Oncological Research

MC1R has been implicated in DNA repair mechanisms, suggesting its potential relevance in oncological studies. Genetic variants of MC1R have been linked to increased susceptibility to basal cell carcinoma and squamous cell carcinoma, suggesting a role in cutaneous oncogenesis. Investigations into melanocortin receptor modulation propose that alterations in Bremelanotide or its derivatives may influence cellular repair pathways, potentially contributing to strategies aimed at mitigating cancer risk or progression^[10]. However, further research is required to determine the mechanistic implications of MC1R modulation in cancer mitigation.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

 

References:

1. Pfaus, J., Giuliano, F., & Gelez, H. (2007). Bremelanotide: an overview of preclinical CNS effects on female sexual function. The journal of sexual medicine, 4 Suppl 4, 269–279. https://doi.org/10.1111/j.1743-6109.2007.00610.x
2. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 9941379, Bremelanotide. Retrieved August 10, 2023 from Pubchem.
3. Renquist, B. J., Lippert, R. N., Sebag, J. A., Ellacott, K. L., & Cone, R. D. (2011). Physiological roles of the melanocortin MC₃ receptor. European journal of pharmacology, 660(1), 13–20. https://doi.org/10.1016/j.ejphar.2010.12.025
4. Renquist, B. J., Lippert, R. N., Sebag, J. A., Ellacott, K. L., & Cone, R. D. (2011). Physiological roles of the melanocortin MC₃ receptor. European journal of pharmacology, 660(1), 13–20. https://doi.org/10.1016/j.ejphar.2010.12.025
5. Vemulapalli, R., Kurowski, S., Salisbury, B., Parker, E., & Davis, H. (2001). Activation of central melanocortin receptors by MT-II increases cavernosal pressure in rabbits by the neuronal release of NO. British journal of pharmacology, 134(8), 1705–1710. https://doi.org/10.1038/sj.bjp.0704437
6. Thurston, L., Hunjan, T., Mills, E. G., Wall, M. B., Ertl, N., Phylactou, M., Muzi, B., Patel, B., Alexander, E. C., Suladze, S., Modi, M., Eng, P. C., Bassett, P. A., Abbara, A., Goldmeier, D., Comninos, A. N., & Dhillo, W. S. (2022). Melanocortin 4 receptor agonism enhances sexual brain processing in women with hypoactive sexual desire disorder. The Journal of Clinical Investigation, 132(19), e152341. https://doi.org/10.1172/JCI152341
7. Adan, R. A., Tiesjema, B., Hillebrand, J. J., la Fleur, S. E., Kas, M. J., & de Krom, M. (2006). The MC4 receptor and control of appetite. British journal of pharmacology, 149(7), 815–827. https://doi.org/10.1038/sj.bjp.0706929
8. Pfaus, J. G., Shadiack, A., Van Soest, T., Tse, M., & Molinoff, P. (2004). Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proceedings of the National Academy of Sciences of the United States of America, 101(27), 10201–10204. https://doi.org/10.1073/pnas.0400491101
9. H. Ji et al., “The Synthetic Melanocortin (CKPV)2 Exerts Anti-Fungal and Anti-Inflammatory Effects against Candida albicans Vaginitis via Inducing Macrophage M2 Polarization,” PLoS ONE, vol. 8, no. 2, Feb. 2013 https://doi.org/10.1371/journal.pone.0056004
10. Maresca V, Flori E, Picardo M. Skin phototype: a new perspective. Pigment Cell Melanoma Res. 2015 Jul;28(4):378-89. doi: 10.1111/pcmr.12365. Epub 2015 Apr 11. PMID: 25786343. https://pubmed.ncbi.nlm.nih.gov/25786343/

Pralmorelin, also referred to as Growth Hormone Releasing Peptide-2 (GHRP-2), is a synthetic pentapeptide classified as a growth hormone secretagogue. Structurally analogous to met-enkephalin^[1], it appears to lack opioid activity and instead interacts with the ghrelin/growth hormone secretagogue receptors (GHS-Rs) to stimulate growth hormone (GH) release. Initially developed as a diagnostic agent for assessing GH deficiency within laboratory settings, Pralmorelin has since become a subject of extensive research due to its potential roles in hunger hormone signal regulation, metabolic modulation, and neuroendocrine signaling.

Studies suggest that Pralmorelin primarily exerts its impacts through its interaction with GHS-Rs, which are widely expressed in the hypothalamus and pituitary gland. Upon binding, it is believed to induce a conformational change in the receptor, activating intracellular signaling cascades mediated by G-proteins. This process may initiate the phospholipase C (PLC) pathway, leading to the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol triphosphate (IP3) and diacylglycerol (DAG). The proposed subsequent release of calcium ions and activation of protein kinase C (PKC) may facilitate GH secretion from somatotroph cells in the anterior pituitary.^{[2, 3]}

Additionally, Pralmorelin appears to stimulate the cyclic adenosine monophosphate (cAMP) pathway, further amplifying GH synthesis and release. In bovine studies, interactions with calcium channels and growth hormone release factor receptors have also been suggested as contributing factors. Apart from GH regulation, Pralmorelin is speculated to influence neuropeptide signaling, particularly by supporting the expression of hunger hormone-stimulating peptides like neuropeptide Y (NPY) and agouti-related peptide (AgRP) while concurrently suppressing melanocyte-stimulating hormone (α-MSH). These mechanisms collectively implicate Pralmorelin in metabolic and neuroendocrine functions beyond GH secretion.

 

Scientific Research and Studies

 

Pralmorelin Peptide and Growth Hormone Deficiency Diagnosis

The insulin tolerance test (ITT) is employed to assess growth hormone (GH) deficiency; however, this method is associated with potentially severe adverse impacts and ancillary impacts. To address these limitations, a clinical study was carried out to determine the possible diagnostic potential of Pralmorelin as an alternative method for evaluating GH deficiency.

As per the study reports^[4], a cohort of 135 research models initially underwent ITT, identifying 77 research models with normal GH responses and 58 with peak GH levels below 3 ng/mL. Following an overnight fasting period, the cohort was introduced to Pralmorelin, with blood samples collected at regular intervals. Researchers state that a distinct peak in GH levels was observed one-hour post peptide introduction in all subjects, with no significant differences based on sex.

That said, a marginal reduction in GH response was noted in research models with higher body mass index (BMI) and advanced cellular age. These findings were reproducible upon repeated evaluation, suggesting consistently elevated GH levels in functional research models compared to those with confirmed GH deficiency. The study findings suggest that Pralmorelin may serve as a reliable diagnostic tool for severe GH deficiency. Its efficacy varies slightly with adiposity and cellular age.

In a separate study^[5], the diagnostic performance of Pralmorelin was compared to conventional stimulatory agents such as arginine and L-dopa in GH deficiency (GHD). Twenty-four research models of GHD and previously introduced to at least one conventional agent were enrolled in the study, which evaluated the introduction of Growth Hormone-Releasing Hormone (GHRH) and GHRP-2. The introduction of Pralmorelin markedly elevated serum GH levels. Among the 21 research models that exhibited a strong GH response, GHRH and GHRP-2 were simultaneously introduced. Subsequently, 15 of these research models underwent intranasal introduction of GHRP-2, which similarly induced a significant GH response.

All research models exposed to Pralmorelin in this study indicated good tolerance, suggesting a favorable profile in younger research models. Notably, reports suggest that Pralmorelin appears to exhibit a distinct advantage as a predictor of pituitary GH secretory capacity, a characteristic not observed with conventional diagnostic agents. These findings highlight the potential of Pralmorelin as an impactful and noninvasive diagnostic tool for researching GH deficiency.

 

Combined Studies with TRH and GnRH

A clinical investigation^[6] studied the impacts of Pralmorelin, Thyrotropin-Releasing Hormone (TRH), and Gonadotropin-Releasing Hormone (GnRH), both individually and in combination, in subjects with prolonged hyposomatotropism, hypogonadism, or hypothyroid complications. The study recruited 33 male research models to assess their endocrine responses to different hormonal stimulation regimens. Over five days, subjects were assigned to one of four groups: placebo, the hourly introduction of Pralmorelin, the combined introduction of Pralmorelin and TRH every hour, or a combination of Pralmorelin, TRH, and GnRH every 90 minutes.

Serum samples were collected on both the first and last nights of the study for endocrine analysis. Results suggest that the combination of GHRP-2, GnRH, and TRH elicited the most pronounced activation of the growth hormone, thyroid-stimulating hormone, and luteinizing hormone axes, potentially influencing metabolic pathways. In contrast, Pralmorelin alone produced minimal endocrine impacts, and, according to the reports, the combination of Pralmorelin and TRH induced only partial hormonal activation compared to the triple-hormone regimen. These findings suggest a potential synergistic interaction between Pralmorelin, GnRH, and TRH in supporting hormonal responses, suggesting their possible role in managing endocrine deficiencies and related metabolic disturbances.

 

Pralmorelin Peptide and Hunger Hormone Signal Modulation

This controlled experiment studies the potential role of Growth Hormone-Releasing Peptide-2 (GHRP-2) in hunger hormone signal regulation. Seven functional male research models were allocated into two groups, with one group receiving a continuous subcutaneous infusion of GHRP-2 and the other receiving a saline placebo over 4.5 hours. Following the infusion, all research models were provided unlimited access to nourishment, and caloric intake was measured to assess differences between the groups.

Results suggested a significant increase in caloric intake among research models exposed to Pralmorelin, with an average intake approximately 36% higher than that of the control group. This reported increase in hunger hormone signals was accompanied by a concurrent elevation in circulating growth hormone (GH) levels, based on which the researchers concluded that “GHRP-2, like ghrelin, increases food intake, suggesting that GHRP-2 [may be] a valuable tool for investigating ghrelin effects on eating behavior.”

These findings support the hypothesis that Pralmorelin may impact hunger hormone stimulation, potentially through its interaction with ghrelin receptors and downstream neuroendocrine signaling pathways.

 

General Pharmacological Impacts

Preclinical investigations^[8] have studied the pharmacological profile of Pralomorelin in animal models. Studies conducted in rabbits and guinea pigs suggest that Pralmorelin does not significantly impact central nervous system function. However, a mild increase in motility was observed in the isolated rabbit ileum, and concentration-dependent support of contraction was noted in the isolated guinea pig ileum.

Beyond these gastrointestinal impacts, no substantial alterations were reported in respiratory, digestive, renal, or circulatory system functions. Researchers concluded that the peptide “has no serious general pharmacological effects at [concentration] levels showing GH-releasing activity in the experimental animals,” and the peptide is speculated to support the diagnosis of “serious GH deficiency and short stature.”^[8]

 

Pralmorelin Peptide and Antioxidative Properties

Studies suggest that Pralmorelin may exert antioxidative impacts, with data suggesting its interaction with CD36, a receptor involved in the uptake of oxidized low-density lipoprotein (OxLDL). This interaction might potentially limit the cellular absorption of OxLDL, a well-regarded contributor to atherogenesis. In murine models deficient in the ApoE gene (ApoE⁻/⁻), prolonged Pralmorelin exposure over 12 weeks was observed to increase circulating insulin-like growth factor-I (IGF-I) levels by approximately 1.2 to 1.6 times baseline values. Additionally, a 66% reduction in circulating interferon-gamma levels was reported.

While Pralmorelin did not appear to significantly alter the extent of atherosclerotic plaque formation, it appeared to reduce superoxide production within the aorta, as supported by data collected concerning dihydroethidium staining. Furthermore, Pralmorelin exposure resulted in a 92% reduction in aortic gene expression of 12/15-lipoxygenase, as well as a downregulation of interferon-gamma and macrophage migration inhibitory factor. Observations in cultured aortic smooth muscle cells suggest that Pralmorelin may counteract peroxide production induced by OxLDL, mitigate IGF-I receptor suppression, and potentially inhibit apoptosis. In macrophages exposed to OxLDL, the peptide is hypothesized to reduce lipid accumulation, further supporting its antioxidative and protective potential against proatherogenic agents.^[9]

 

Pralmorelin Peptide and Muscular Tissue Preservation

Murine models of thermal injury suggest that Pralmorelin may play a role in mitigating muscular tissue catabolism by reducing proinflammatory markers such as interleukin-6 (IL-6) and E3 ubiquitin ligases (MuRF-1 and MAFbx), both of which are implicated in muscular tissue degradation under critical conditions. Additionally, researchers propose that Pralmorelin may directly attenuate total muscle protein breakdown, indicating a potential muscle-sparing impact. Case studies further suggest that the peptide may contribute to muscular tissue hypertrophy and mass gain.^[11]

 

Pralmorelin Peptide and Inflammation

To further investigate Pralmorelin’s impacts on oxidative stress and inflammation, murine models of acute lung injury were studied following peptide introduction. Findings suggest that Pralmorelin exposure may reduce pulmonary edema, neutrophil infiltration, and proinflammatory cytokine levels. Additionally, the peptide appears to suppress nuclear factor-kappa B (NF-κB) activation, a key regulator of inflammatory cascades often associated with tissue damage. These findings^[12] suggest that Pralmorelin may exert protective impacts against inflammation-induced tissue injury.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

 

References:

1. Garcia JM, Merriam GR, Kargi AY. Growth Hormone in Aging. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext. South Dartmouth (MA): MDText.com https://www.ncbi.nlm.nih.gov/books/NBK279163/
2. Yin, Y., Li, Y., & Zhang, W. (2014). The growth hormone secretagogue receptor: its intracellular signaling and regulation. International journal of molecular sciences, 15(3), 4837–4855. https://doi.org/10.3390/ijms15034837
3. Sinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., Pastuszak, A. W., & Lipshultz, L. I. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational andrology and urology, 9(Suppl 2), S149–S159. https://doi.org/10.21037/tau.2019.11.30
4. Roh SG, He ML, Matsunaga N, Hidaka S, Hidari H. Mechanisms of action of growth hormone-releasing peptide-2 in bovine pituitary cells. J Anim Sci. 1997 Oct;75(10):2744-8. doi: 10.2527/1997.75102744x. PMID: 9331879. https://pubmed.ncbi.nlm.nih.gov/9331879/
5. Asad Rahim, Stephen M. Shalet, in Growth Hormone Secretagogues, 1999. Does desensitization to growth hormone secretagogues occur? https://www.sciencedirect.com/
6. Van den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, Iranmanesh A, Veldhuis JD, Bouillon R. The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clin Endocrinol (Oxf). 2002 May;56(5):655-69. doi: 10.1046/j.1365-2265.2002.01255.x. PMID: 12030918. https://pubmed.ncbi.nlm.nih.gov/12030918/
7. Laferrère, Blandine et al. Growth hormone-releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. The Journal of Clinical Endocrinology and Metabolism vol. 90,2 (2005): 611-4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2824650/
8. Furuta S, Shimada O, Doi N, Ukai K, Nakagawa T, Watanabe J, Imaizumi M. General pharmacology of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. Arzneimittelforschung. 2004;54(12):868-80. doi: 10.1055/s-0031-1297042. PMID: 15646371. https://pubmed.ncbi.nlm.nih.gov/15646371/
9. Titterington JS, Sukhanov S, Higashi Y, Vaughn C, Bowers C, Delafontaine P. Growth hormone-releasing peptide-2 suppresses vascular oxidative stress in ApoE-/- mice but does not reduce atherosclerosis. Endocrinology. 2009 Dec;150(12):5478-87. doi: 10.1210/en.2009-0283. Epub 2009 Oct 9. PMID: 19819949; PMCID: PMC2795722. https://pmc.ncbi.nlm.nih.gov/articles/PMC2795722/
10. Sheriff, S., Joshi, R., Friend, L. A., James, J. H., & Balasubramaniam, A. (2009). Ghrelin receptor agonist, GHRP-2, attenuates burn injury-induced MuRF-1 and MAFbx expression and muscle proteolysis in rats. Peptides, 30(10), 1909–1913. https://doi.org/10.1016/j.peptides.2009.06.029
11. Sigalos, J. T., & Pastuszak, A. W. (2018). The Safety and Efficacy of Growth Hormone Secretagogues. Sexual medicine reviews, 6(1), 45–53. https://doi.org/10.1016/j.sxmr.2017.02.004
12. Li, G., Li, J., Zhou, Q., Song, X., Liang, H., & Huang, L. (2010). Growth hormone-releasing peptide-2, a ghrelin agonist, attenuates lipopolysaccharide-induced acute lung injury in rats. The Tohoku journal of experimental medicine, 222(1), 7–13. https://doi.org/10.1620/tjem.222.7

The Tesamorelin & CJC-1295 (Mod GRF 1-29) & Ipamorelin peptide blend represents a combination of synthetic peptides, each with distinct properties that researchers have hypothesized may hold mechanisms for stimulating growth hormone (GH) synthesis and secretion. Although structurally and functionally unique, these peptides appear to share a common focus on modulating the endocrine system’s GH regulatory axis. This blend has been the subject of various research efforts to explore its biochemical properties, interactions with receptors, and physiological effects.

 

Tesamorelin Peptide

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), engineered to resemble the natural peptide that scientists consider to be responsible for stimulating GH secretion. Structurally, Tesamorelin consists of 44 amino acids and incorporates specific modifications to enhance its stability against enzymatic degradation. One notable modification is the introduction of a trans-3-hexenoic acid group at its C-terminus, often referred to as an omega-amino acid modification.^[1] This alteration is hypothesized to improve resistance to enzymatic breakdown, prolonging its functional lifespan in biological systems. Additionally, the N-terminal acetylation (CH₃CO-) has been suggested to further contribute to its structural resilience and bioactivity. These modifications result in the designation N-(trans-3-hexenoyl)-[Tyr1]hGRF(1–44)NH2 acetate.

Tesamorelin’s mechanism of action is thought to involve binding to GHRH receptors located in the hypothalamus and pituitary gland,^[1] thereby triggering the release of endogenous GH. This proposed mechanism has garnered interest in exploring its implications for protein metabolism, lipid oxidation, and cellular growth processes.

 

CJC-1295 (Mod GRF 1-29) Peptide

CJC-1295 (Mod GRF 1-29) is a synthetic derivative of the functional segment of GHRH, comprising 29 amino acids. This peptide is often described as a tetrasubstituted variant designed to resist enzymatic degradation and extend its half-life. Unlike its predecessor with a Drug Affinity Complex (DAC), the Mod GRF 1-29 variant lacks the DAC but appears to have retained significant stability and activity. Research suggests that CJC-1295 interacts with GHRH receptors in the pituitary gland, where it may stimulate GH secretion.

Its proposed mechanism mimics that of GHRH, potentially enhancing protein synthesis, promoting muscle hypertrophy, and influencing metabolic pathways.^[2] The peptide’s engineered design aims to maintain functionality while reducing susceptibility to degradation, making it a key component of this peptide blend.

 

Ipamorelin Peptide

Ipamorelin is a synthetic pentapeptide and a selective agonist for the ghrelin receptor, also known as the growth hormone secretagogue (GHS) receptor. This receptor is predominantly expressed in the pituitary gland, where its activation may stimulate the release of GH. Ipamorelin exhibits high specificity for the GHS receptor, with minimal interaction with other hormonal systems, reducing the likelihood of off-target action.

Research suggests that Ipamorelin’s apparent selective binding to the GHS receptor might enhance GH secretion without altering levels of other hormones, such as cortisol or prolactin.^[3] This unique mechanism positions Ipamorelin as a potential tool for investigating GH-related physiological processes, including growth, repair, and metabolic regulation.

This tri-peptide blend appears to combine Tesamorelin’s GHRH receptor affinity, CJC-1295’s enhanced stability and activity, and Ipamorelin’s selective ghrelin receptor stimulation. Together, these peptides may offer synergistic effects on GH secretion, which warrants further investigation through controlled research studies.

 

Scientific Research and Studies

 

Tesamorelin, CJC-1295 (Mod GRF 1-29), and Ipamorelin Blend and the Pituitary Gland

The peptide blend comprising Tesamorelin, CJC-1295 (Mod GRF 1-29), and Ipamorelin is speculated to potentially interact with the pituitary gland, primarily through receptor-specific binding that may modulate the secretion of growth hormone (GH).

Tesamorelin and CJC-1295 (Mod GRF 1-29) are analogs of growth hormone-releasing hormone (GHRH) that appear to target GHRH receptors on somatotrophs in the anterior pituitary. Research suggests that their interaction may induce receptor conformational changes, activating downstream intracellular signaling cascades.^[4] Specifically, these peptides are hypothesized to stimulate adenylate cyclase, leading to the conversion of adenosine triphosphate (ATP) into cyclic adenosine monophosphate (cAMP). The resulting elevation of cAMP levels is thought to activate protein kinase A (PKA), which phosphorylates various intracellular targets. This signaling cascade is believed to culminate in the synthesis and secretion of human growth hormone (hGH). The hGH released from somatotroph cells may also facilitate the production of insulin-like growth factor-1 (IGF-1), deemed a critical mediator of growth hormone activity.

CJC-1295 (Mod GRF 1-29) exhibits notable structural modifications, including four amino acid substitutions, which may enhance its resistance to enzymatic degradation. This increased stability is reported to extend its half-life, improving its pharmacokinetic profile. Additionally, these modifications allow a proportion of the peptide to covalently bind to serum albumin, thereby prolonging its duration of action. Trace binding to fibrinogen and immunoglobulin G (IgG) has also been observed. These properties collectively suggest a sustained mechanism of action, with a potential for increased biological activity.^[5]

Ipamorelin, in contrast, is a selective agonist for the ghrelin receptor, also referred to as the growth hormone secretagogue receptor (GHSR). This peptide is believed to bind to GHSR on somatotroph cells, initiating signaling pathways that may promote GH secretion. Unlike some other secretagogues, Ipamorelin appears to exert a high degree of specificity for GHSR, with apparently minimal off-target effects on other endocrine pathways, including prolactin and adrenocorticotropic hormone (ACTH) regulation.^[6]

In vitro studies^[7] suggest that Ipamorelin binding to GHSR activates phospholipase C (PLC), which catalyzes the generation of inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 may mobilize calcium ions (Ca2+) from intracellular stores, while DAG is thought to activate protein kinase C (PKC). These intracellular events potentially facilitate the exocytosis of vesicles containing GH from somatotroph cells. This process underscores the peptide’s role in GH secretion through precise intracellular signaling mechanisms.

The combined properties of Tesamorelin, CJC-1295 (Mod GRF 1-29), and Ipamorelin suggest a synergistic effect on pituitary function. Tesamorelin and CJC-1295 (Mod GRF 1-29) focus on GHRH receptor pathways, while Ipamorelin appears to activate the GHSR, providing complementary mechanisms to stimulate GH release. These peptides collectively indicate complex interactions with the pituitary gland, potentially enhancing GH secretion through distinct yet interconnected molecular pathways. Such findings highlight their potential implications in regulating growth hormone activity and associated metabolic processes. Further research is necessary to elucidate the full scope of their physiological effects and research applications.

 

Tesamorelin, CJC-1295 (Mod GRF 1-29), and Ipamorelin and Cardiovascular Action

The potential cardiovascular effects of Tesamorelin, Modified GRF (CJC-1295), and Ipamorelin have been studied with an emphasis on cardiac repair and lipid metabolism. Following myocardial infarction (MI), cardiac tissue often undergoes scarring, which can impair heart function, including ejection fraction and contractility. Research in animal models suggests that growth hormone secretagogues may possibly enhance post-MI cardiac repair. Observed outcomes include reduced infarct size, improved cardiac ejection fraction, and restoration of overall cardiac function.^[8]

Ipamorelin’s activation of the GHS-R1a receptor is hypothesized to exert a possible cardioprotective effect through positive inotropic properties. Researchers elucidate that, “Through activation of GHS-R1a, secretagogues produced a positive inotropic effect on ischemic cardiomyocytes and protected them from I/R injury, likely by safeguarding or restoring p-PLB (and hence SR Ca2+ content) to facilitate the maintenance or recovery of normal cardiac contractility.”

Additionally, Tesamorelin, while primarily recognized for its lipodystrophy-reducing properties, has exhibited potential cardiovascular action, particularly in HIV-positive models. Some studies highlight its potential to lower triglycerides, total cholesterol, and non-HDL cholesterol levels,^[9] suggesting a broader impact on lipid metabolism and cardiovascular function. These findings collectively underscore the potential of this peptide blend to modulate cardiac function and lipid profiles.

 

Tesamorelin, CJC-1295 (Mod GRF 1-29), and Ipamorelin and Effect on Gastrointestinal Tract

The peptide blend comprising Tesamorelin, Modified GRF (CJC-1295), and Ipamorelin may hold varying degrees of influence on the gastrointestinal (GI) tract through distinct mechanisms. Tesamorelin appears to enhance gastric emptying and gastrointestinal motility, as observed in preclinical studies. This action suggests its potential utility in addressing motility disorders or delayed gastric emptying.

Modified GRF, while exhibiting minimal direct effects on motility, appears to support GI function by improving gut barrier integrity and mitigating intestinal inflammation. This effect has been primarily studied in animal models of colitis, where the peptide appeared to host anti-inflammatory properties and potential contributions to the restoration of gut homeostasis.

Ipamorelin, as a selective agonist of the ghrelin receptor, is posited to exert effects through receptor activation within the GI tract. Upon binding to ghrelin receptors, Ipamorelin may stimulate gut motility, improve nutrient absorption, and contribute to tissue repair following gastrointestinal injury. Furthermore, preclinical research indicates its potential to mitigate inflammation and promote recovery in various models of GI injury. According to the studies, Ipamorelin may “increase total body fat percentages,” suggesting the peptide is a “potent and selective stimulator of GH that [may] significantly influence the GI system, body composition, and adiposity.”^[10]

 

Synergistic Potential of Tesamorelin, CJC-1295 (Mod GRF 1-29), and Ipamorelin Peptides

The combination of Tesamorelin, Modified GRF (CJC-1295), and Ipamorelin has been proposed by its researchers to enhance growth hormone (GH) secretion through distinct yet complementary mechanisms of action. Studies suggest that Tesamorelin and Modified GRF, when combined, may produce a synergistic increase in GH levels, surpassing the effects of either peptide alone.^[11] This blend is also speculated to cause reductions in visceral adipose tissue, particularly in models of HIV-associated lipodystrophy, though this effect may have been reversed upon study cessation.

Beyond GH secretion, this peptide combination, as per the research, is suggested to support improved sleep-wake cycles, increased behavioral mood, energy, and sustained GH production over time. Together, these peptides may also synergistically enhance insulin-like growth factor 1 (IGF-1) levels, potentially leading to improved muscle growth, bone density, cognitive function, and cellular repair, making this blend a promising tool for studies exploring diverse metabolic and physiological challenges.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

 

References:

1. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 9831659, Ipamorelin. https://pubchem.ncbi.nlm.nih.gov/compound/Ipamorelin.
2. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 56841945. https://pubchem.ncbi.nlm.nih.gov/compound/56841945.
3. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 16137828, Tesamorelin. https://pubchem.ncbi.nlm.nih.gov/compound/Tesamorelin
4. Spooner, L. M., & Olin, J. L. (2012). Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. The Annals of pharmacotherapy, 46(2), 240–247. https://doi.org/10.1345/aph.1Q629
5. Zhou, F., Zhang, H., Cong, Z., Zhao, L. H., Zhou, Q., Mao, C., Cheng, X., Shen, D. D., Cai, X., Ma, C., Wang, Y., Dai, A., Zhou, Y., Sun, W., Zhao, F., Zhao, S., Jiang, H., Jiang, Y., Yang, D., Eric Xu, H., … Wang, M. W. (2020). Structural basis for activation of the growth hormone-releasing hormone receptor. Nature communications, 11(1), 5205. https://doi.org/10.1038/s41467-020-18945-0
6. Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 Mar;9(Suppl 2):S149-S159. doi: 10.21037/tau.2019.11.30. PMID: 32257855; PMCID: PMC7108996 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108996/
7. Jiménez-Reina, L., Cañete, R., de la Torre, M. J., & Bernal, G. (2002). Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histology and histopathology, 17(3), 707–714. https://doi.org/10.14670/HH-17.707
8. Ma Y, Zhang L, Edwards JN, Launikonis BS, Chen C. Growth hormone secretagogues protect mouse cardiomyocytes from in vitro ischemia/reperfusion injury through regulation of intracellular calcium. PLoS One. 2012;7(4):e35265. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0035265 Epub 2012 Apr 6. PMID: 22493744; PMCID: PMC3320867. https://pmc.ncbi.nlm.nih.gov/articles/PMC3320867/
9. Stanley TL, Falutz J, Marsolais C, Morin J, Soulban G, Mamputu JC, Assaad H, Turner R, Grinspoon SK. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012 Jun;54(11):1642-51. doi: 10.1093/cid/cis251. Epub 2012 Apr 10. PMID: 22495074; PMCID: PMC3348954. https://pubmed.ncbi.nlm.nih.gov/22495074/
10. Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 Mar;9(Suppl 2):S149-S159. doi: 10.21037/tau.2019.11.30. PMID: 32257855; PMCID: PMC7108996 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108996/
11. Bedimo R. Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy. HIV AIDS (Auckl). 2011;3:69-79. doi: 10.2147/HIV.S14561. Epub 2011 Jul 10. PMID: 22096409; PMCID: PMC3218714. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218714/

The Modified GRF 1-29 and Ipamorelin blend represents a significant advancement in peptide-based research, particularly for its potential to influence growth hormone secretion and metabolic processes. This synergistic combination pairs two complementary peptides with distinct but interconnected roles, which is considered pivotal in this branch of scientific research.

Modified GRF 1-29, a stabilized analog of growth hormone-releasing hormone (GHRH), is reportedly designed to increase growth hormone release by targeting GHRH receptors on somatotroph cells in the anterior pituitary gland.^[1] Its structural modifications, which replace four amino acids in the native sequence, are speculated to confer enhanced stability and bioavailability, potentially making it more resistant to enzymatic degradation.

Ipamorelin, a synthetic pentapeptide and selective growth hormone secretagogue (GHS), is suggested to operate by mimicking the action of ghrelin, a naturally occurring hormone involved in hunger signaling and growth hormone release. By activating growth hormone secretagogue receptor 1-alpha (GHS-R1a) in the pituitary, Ipamorelin reportedly initiates intracellular signaling pathways that stimulate the secretion of growth hormone while maintaining high selectivity to avoid affecting other hormones such as cortisol or prolactin.

Together, these peptides are speculated to offer a powerful mechanism of action where Ipamorelin may provide rapid, short-term stimulation of growth hormone release, while Modified GRF 1-29 may ensure a more sustained response by activating complementary signaling pathways. This dual-action mechanism, achieved through distinct receptor interactions, might create an extended-release profile that researchers suggest may lead to increased growth hormone activity compared to studying either peptide alone.^[2]

 

Scientific Research and Studies

 

Modified GRF 1-29 & Ipamorelin Blend and Growth Hormone

A series of studies^[3] conducted in 1998 appears to provide critical insights into the function of the Modified GRF 1-29 and Ipamorelin blend in the function of growth hormone secretion. Experimental models, including rat pituitary glands, anesthetized rats, and conscious swine, were utilized to evaluate the peptides’ activity. Findings suggest that both Modified GRF 1-29 and Ipamorelin may act as agonists of GHRP-like receptors, binding to these targets to reportedly stimulate significant increases in growth hormone secretion. It also appears that the peptides exhibited high receptor specificity. While other growth hormone secretagogues often triggered elevations in additional hormones such as cortisol and ACTH, Ipamorelin and Modified GRF 1-29 “very surprisingly, did not [appear to] release ACTH or cortisol in levels significantly”, reportedly even at significantly high concentrations compared to other similar peptides.

Further research in 1999 sought to extend these findings through clinical trials. In this study,^[4] eight research models were introduced with growth hormone secretagogues at progressively increasing concentrations, with amounts adjusted every 15 minutes over a two-hour period. Based on the results, it was suggested that there was a marked elevation in circulating growth hormone levels throughout the study duration, suggesting a concentration-dependent response to the blend.

These findings support the hypothesis that the combination of Modified GRF 1-29 and Ipamorelin may provide a synergistic and sustained increase of growth hormone release, laying the groundwork for future research into their potential.

 

Cardiac Function

In a pilot study,^[5] experimental models were introduced with growth hormone-releasing hormone (GHRH) peptide analogs, including Modified GRF 1-29, to evaluate their potential effects on cardiac function. Findings from this research suggest that the peptides may positively influence myocardial function, particularly in models of myocardial infarction. The study hypothesized that Modified GRF 1-29 might enhance cardiac performance by increasing heart rate and improving blood pumping efficiency.

 

Modified GRF 1-29 & Ipamorelin Blend and Potency

Preliminary investigations have provided significant hypotheses into the potency of the Modified GRF 1-29 and Ipamorelin blend, specifically its potential compared to regular GRF 1-29. In one study,^[6] experimental rats were exposed to GHRH peptide analogs, including Modified GRF 1-29. Results suggested that the synthetic analog may have greater efficacy in stimulating growth hormone release than its unmodified counterpart. This enhanced potency appears to be attributed to the structural modifications in Modified GRF 1-29, which may improve its stability and receptor binding efficiency, allowing for sustained biological activity over time.

 

Modified GRF 1-29 & Ipamorelin Blend and the Pituitary

The efficacy of the blend in promoting growth hormone secretion is closely linked to its interaction with GHRH receptors on somatotroph cells in the anterior pituitary gland. The binding of the peptide to these receptors is hypothesized to act as a catalyst for a cascade of intracellular signaling events. One such pathway involves the activation of adenylyl cyclase, which converts ATP into cyclic adenosine monophosphate (cAMP). The elevation of cAMP levels activates protein kinase A (PKA), leading to the phosphorylation of proteins, such as voltage-dependent calcium channels on the somatotroph cell membrane.^[7] This phosphorylation facilitates calcium ion influx, which reportedly initiates the secretion of growth hormone from the cell’s secretory vesicles into the bloodstream.

Similarly, Ipamorelin appears to function with a distinct mechanism of action by selectively targeting the GHS-R1a receptors in the anterior pituitary. The peptide supposedly interacts with the N-terminal region of these receptors through hydrogen bonding and van der Waals forces, inducing conformational changes that activate intracellular G-protein signaling pathways. Specifically, GHS-R1a is thought to couple with Gαq/11 subunits, which subsequently activate phospholipase C (PLC). PLC cleaves phosphatidylinositol 4, 5-bisphosphate (PIP2) into two critical secondary messengers: inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 binds to receptors on the endoplasmic reticulum, prompting the release of calcium ions (Ca2+), which, in turn, reportedly activates downstream proteins that regulate growth hormone secretion.^[8]

 

Modified GRF 1-29 & Ipamorelin Blend and the Gastrointestinal System

In a recent investigation, the potential influence of Ipamorelin on gastric motility was examined, with particular emphasis on its capacity to expedite gastric emptying. The study utilized a specialized technique to assess gastric emptying by quantifying the percentage of radioactivity remaining in the stomach 15 minutes following the introduction of a radiolabeled substance via intragastric gavage. The researchers observed that surgical manipulation of the abdominal region may have contributed to a delayed gastric emptying rate, as reported by the researchers in the control group, which received a vehicle substance. In contrast, Ipamorelin appeared to significantly accelerate the gastric emptying process relative to the control group, suggesting that Ipamorelin may potentially increase the rate of gastric emptying.

Subsequent analyses studied the possible effect of Ipamorelin on the contractile activity of gastric smooth muscle, which was induced by both acetylcholine and electrical field stimulation. The results suggested that surgical intervention and manipulation of the gastrointestinal tract in these animal models may markedly attenuate the contractile responses of gastric smooth muscle to these stimuli. Notably, this suppression appeared to be reversed when both Ipamorelin and ghrelin were co-introduced, hinting that Ipamorelin may not only facilitate gastric smooth muscle contractility but also potentially mitigate any inhibitory effects induced by certain surgical interventions.^[9]

 

Modified GRF 1-29 & Ipamorelin Blend and Appetite Regulation

The potential effects of Ipamorelin on ghrelin receptors suggest a potential for appetite support and subsequent weight increase In a controlled study,^[10] experimental models reportedly “induced a small (15%) increase in body weight by 2 weeks” following peptide exposure. Researchers propose that this compound may have disproportionately increased fat pad mass relative to total body mass, which may lead to a discernible rise in fat as measured by dual-energy X-ray absorptiometry (DEXA). Further data indicated that Ipamorelin may have elevated serum leptin levels, a hormone associated with energy balance and appetite regulation. This observation has led to the hypothesis that increased food intake may play a role in the observed weight gain in the Ipamorelin-exposed research models. The researchers suggest that growth hormone secretagogues (GHSs), such as Ipamorelin, may contribute to fat cell accumulation via mechanisms independent of growth hormone, potentially including an increase in caloric consumption.

 

Modified GRF 1-29 & Ipamorelin Blend and Bone Density

In a study conducted with murine models, the effects of Ipamorelin on bone mass were evaluated through the introduction of both Ipamorelin and a control substance. Real-time DEXA was utilized to monitor alterations in bone mineral content, focusing on specific regions such as the femur and L6 vertebrae. Upon completion of the experimental period, mid-diaphyseal peripheral quantitative computed tomography (pQCT) scans were performed on the femurs of the models under observation. Preliminary findings suggest that Ipamorelin may be associated with an increase in weight and a potential rise in bone mineral content (BMC) in the tibia and vertebrae, as indicated by DEXA results when compared to the control group. Moreover, pQCT data point to an increase in cortical BMC, likely due to an expansion of the bone’s cross-sectional area. The researchers also hypothesize that minor stimulatory effects on linear bone growth may not have been statistically significant in the growth hormone (GH) and Ipamorelin-exposed cohorts, potentially due to the scope of the study.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

 

References:

1. The Discovery of Growth Hormone-Releasing Hormone: An Update https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2826.2008.01740.x
2. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999 Sep;16(9):1412-6. doi: 10.1023/a:1018955126402. PMID: 10496658. https://pubmed.ncbi.nlm.nih.gov/10496658/
3. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/
4. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999 Sep;16(9):1412-6. doi: 10.1023/a:1018955126402. PMID: 10496658. https://pubmed.ncbi.nlm.nih.gov/10496658/
5. Schally AV, Zhang X, Cai R, Hare JM, Granata R, Bartoli M. Actions and Potential Therapeutic Applications of Growth Hormone-Releasing Hormone Agonists. Endocrinology. 2019 Jul 1;160(7):1600-1612. doi: 10.1210/en.2019-00111. PMID: 31070727. https://pubmed.ncbi.nlm.nih.gov/31070727/
6. Schally AV, Zhang X, Cai R, Hare JM, Granata R, Bartoli M. Actions and Potential Therapeutic Applications of Growth Hormone-Releasing  Hormone Agonists. Endocrinology. 2019 Jul 1;160(7):1600-1612. https://pubmed.ncbi.nlm.nih.gov/31070727/
7. Sinha, D. K., Balasubramanian, A., Tatem, A. J., Rivera-Mirabal, J., Yu, J., Kovac, J., Pastuszak, A. W., & Lipshultz, L. I. (2020). Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational andrology and urology, 9(Suppl 2), S149–S159.  https://doi.org/10.21037/tau.2019.11.30
8. Bill, C. A., & Vines, C. M. (2020). Phospholipase C. Advances in experimental medicine and biology, 1131, 215–242. https://doi.org/10.1007/978-3-030-12457-1_9
9. Lall, S., Tung, L. Y., Ohlsson, C., Jansson, J. O., & Dickson, S. L. (2001). Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochemical and biophysical research communications, 280(1), 132–138. https://doi.org/10.1006/bbrc.2000.4065
10. Sabrina Lall, Loraine Y.C Tung, Claes Ohlsson, John-Olov Jansson, Suzanne L Dickson, Growth Hormone (GH)-Independent Stimulation of Adiposity by GH Secretagogues, Biochemical and Biophysical Research Communications, Volume 280, Issue 1, 2001, Pages 132-138, ISSN 0006-291X, https://doi.org/10.1006/bbrc.2000.4065
11. Image 1 source: National Center for Biotechnology Information. PubChem Compound Summary for CID 91976842, CJC1295 Without DAC. https://pubchem.ncbi.nlm.nih.gov/compound/CJC1295-Without-DAC
12. Image 2 source: National Center for Biotechnology Information (2024). PubChem Compound Summary for CID 9831659, Ipamorelin. https://pubchem.ncbi.nlm.nih.gov/compound/Ipamorelin.

AHK-Cu is often described as a small tripeptide (alanine–histidine–lysine) that may incorporate a copper ion bound to the residues of alanine and histidine.^[1] Some researchers believe that the amino acid sequence might be endogenously occurring. Investigations by qualified researchers also propose that AHK-Cu peptide might have a role in modulating several processes in endothelial cells, such as hair follicle cells, such as growth, differentiation, and programmed cell death.

 

Mechanism of Action

AHK-Cu peptide has been examined for its possible involvement in hair growth and the maintenance of dermal tissue. In some studies, it appears to act on fibroblasts, which are cells that might produce and maintain the extracellular matrix (ECM)—a complex network of proteins, including collagen and elastin, that provides structural support around cells. Fibroblasts may also secrete certain signaling molecules, such as Vascular Endothelial Growth Factor (VEGF). Fibroblasts are typically recognized as cells that may synthesize essential structural proteins, including collagen. VEGF refers to a protein family that may be crucial for forming new blood vessels, a process termed angiogenesis. By increasing VEGF production, AHK-Cu peptide might strengthen blood vessel formation, possibly supporting how nutrients and oxygen are delivered to various tissues, including hair follicles.^[2] This route may be relevant for hair growth, as additional nutrients and oxygen may theoretically support follicle function.

AHK-Cu peptide has also been linked to a possible influence on Transforming Growth Factor Beta 1 (TGF-β1). TGF-β1, sometimes viewed as a critical cytokine, is studied for its role in cell growth, immune regulation, and wound repair. If AHK-Cu peptide happens to lower TGF-β1 levels, it might modify certain cell processes or immune responses, though the extent of this potential remains speculative. Because AHK-Cu peptide contains a copper ion, it might engage in enzymatic pathways that influence collagen and elastin production. Collagen and elastin are ECM proteins that may help maintain skin structure elasticity and structural stability. Copper ions themselves have been explored for possible antioxidant activity, which may mean they scavenge free radicals or support other protective mechanisms in cells.
 

Scientific Research and Studies

 

AHK-Cu Peptide and Hair Follicles

In a recent study ^[3], the researchers examined whether AHK-Cu peptide might influence hair growth in laboratory settings. They observed that this peptide may support the elongation of hair follicles and might also encourage the proliferation of dermal papilla cells (DPCs). DPCs are often viewed as specialized fibroblasts with a suggested capacity to promote hair follicle maturation. The same study additionally proposed that AHK-Cu peptide may reduce the frequency of apoptotic (programmed cell death) DPCs. Subsequent analyses indicated that the peptide might elevate the ratio of Bcl-2 (B-cell lymphoma 2) to Bax (Bcl-2-associated X protein). Bcl-2 is frequently seen as an anti-apoptotic factor that may impede cell death, whereas Bax is thought to be pro-apoptotic and might contribute to cell death pathways.

Investigators further speculated that AHK-Cu peptide might decrease cleaved caspase-3 and poly (ADP-ribose) polymerase (PARP) levels—biomolecules often evaluated as markers of cell death. Because a higher Bcl-2/Bax ratio is commonly associated with fewer apoptotic events, the study proposed that such a shift in the ratio may favor cell survival and possibly maintain viable DPC populations. Ultimately, the authors concluded the following: “The present study proposed that AHK-Cu promotes the growth of […] hair follicles, and this stimulatory effect may occur due to stimulation of the proliferation and the preclusion of the apoptosis of DPCs.”^[3]

 

AHK-Cu Peptide and Antioxidative Potential

AHK-Cu is frequently mentioned as having strong antioxidant properties, potentially attributable to its distinctive tripeptide structure, which includes alanine, histidine, and lysine, often bound to a copper ion. Based on these purported antioxidant characteristics, some investigations have posited that AHK-Cu peptide may help protect and restore hair follicle size, ultimately increasing hair growth.

Scientists also speculate that AHK-Cu’s antioxidant potential might have broader functions, possibly involving cellular aging, wound repair, and related physiological processes. These observations reflect the notion that AHK-Cu peptide might help protect collagen from oxidative stress and damage. Collagen—a principal protein for upholding tissue integrity—is often viewed as indispensable for dermal layer and hair cell integrity and overall functionality.^[4]

 

AHK-Cu Peptide and Dermal Cells

Preliminary laboratory work has indicated that “AHK-Cu increases the growth and viability of dermal fibroblasts while stimulating the production of collagen.” Observations suggest that, in certain experiments, the presence of AHK peptide alone appeared to promote both fibroblast viability and replication, in addition to supporting the production of collagen type I.

Investigations measuring collagen type I levels after exposing normal dermal fibroblasts to different AHK concentrations suggested a marked rise in collagen synthesis, which was at times documented to be around threefold compared to control groups.^[5] These findings point to the possibility that AHK might help replenish or maintain the extracellular matrix, which comprises various proteins that form the supportive framework of tissues. By theoretically impacting collagen levels in dermal fibroblasts, AHK-Cu peptide might aid dermal layer functionality, although researchers continue to explore the extent of its potential.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

 

References:

1. Kapoor R, Shome D, Vadera S, Kumar V, Ram MS. QR678 & QR678 Neo Hair Growth Formulations: A Cellular Toxicity & Animal Efficacy Study. Plast Reconstr Surg Glob Open. 2020 Aug 25;8(8):e2843. doi: 10.1097/GOX.0000000000002843. PMID: 32983753; PMCID: PMC7489598.
2. Sadgrove NJ, Simmonds MSJ. Topical and nutricosmetic products for healthy hair and dermal anti-aging using “dual-acting” (2 for 1) plant-based peptides, hormones, and cannabinoids. FASEB Bioadv. 2021 Jun 6;3(8):601-610. doi: 10.1096/fba.2021-00022. PMID: 34377956; PMCID: PMC8332470.
3. Pyo HK, Yoo HG, Won CH, Lee SH, Kang YJ, Eun HC, Cho KH, Kim KH. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007 Jul;30(7):834-9. doi: 10.1007/BF02978833. PMID: 17703734.
4. Kecel-Gunduza, S., Kocb, E., Bicaka, B., Kokcub, Y., Ozela, A. E., & Akyuzc, S. (2020). IN SILICO ANALYSIS FOR CHARACTERIZING THE STRUCTURE AND BINDING PROPERTIES OF ALA-HIS-LYS (AHK) TRIPEPTIDE. The Online Journal of Science and Technology-July, 10(3).
5. Patt, L. M., & Procyte, A. (2009). Neova® DNA Repair Factor Nourishing Lotion Stimulates Collagen and Speeds Natural Repair Process. skin, 1, 2.

Mechano-growth factor (MGF) is posited to be a short, 24–24-amino-acid segment that may appear within one of the isoforms of insulin-like growth factor-1 (IGF-1).^[1] For context, IGF-1 is widely regarded as one of the most powerful endogenous factors driving cellular growth and proliferation. One of its isoforms produced via the IGF-1 gene appears to be the IGF-IEc (otherwise referred to as full-length MGF) isoform. Once produced, this isoform might be cleaved to generate both mature IGF-I—a 70–amino-acid protein common to all IGF-I isoforms—and a distinct 24–amino-acid peptide termed as “MGF.” The name MGF is based on observations that IGF-IEc gene expression may become upregulated when muscle cells are subjected to mechanical stress (for example, exercise). MGF is also termed MGF-Ct24E, MGF-24aa-E, or E-domain of IGF-1Ec. However, endogenous MGF has not been isolated. In research models like these, scientists have studied only synthetic MGF.^[2]

 

Mechanism of Action

Researchers have posited that MGF may promote muscle cell hypertrophy and repair, but via mechanisms that may differ compared to native IGF-1. IGF-I itself is posited to bind to the IGF-1 receptor on muscle cells and triggers the PI3K–Akt pathway, a signaling route that often promotes cell survival, differentiation, and controlled proliferation. In contrast, several in vitro studies have noted that synthetic MGF does not appear to activate Akt robustly. Instead, they may increase phosphorylation of ERK (particularly ERK5) and support MEF2C activity—two components more strongly linked to gene transcription events that may drive an increase in cellular size, aka hypertrophy.^[1][2] In other words, researchers posit that synthetic MGF seemingly steers the cell toward a gene expression profile that bolsters muscle cell growth in ways that might not precisely mirror the mature IGF-1 response.

 

Scientific Research and Studies

 

MGF and Muscle Cell Survival

Muscle cell damage is typically associated with increased oxidation levels, cellular death, and replacement with fibrotic tissue. A study indicates that MGF appears to reduce fibrosis in injured skeletal muscle cells, possibly by decreasing the synthesis of collagen types I and III.^[3] This reduction in collagen deposition might be mediated by the downregulation of pro-fibrotic cytokines such as TGF-β, which is thought to play a central role in fibrosis. Additionally, MGF may modulate the inflammatory environment within the injured muscle cells. MGF was associated with lowered levels of pro-inflammatory cytokines, including TNF-α, IL-1β, and IFN-γ, suggesting that MGF might help attenuate excessive inflammatory responses that might otherwise impair recovery of muscular tissue. Furthermore, MGF potentially affects oxidative stress within the injured tissue. The study found that MGF led to a decrease in the expression of gp91phox, a key subunit of NADPH oxidases involved in the production of reactive oxygen species (ROS). By reducing oxidative stress, MGF may create a more favorable environment for muscle cell survival and tissue repair. Additionally, MGF might influence extracellular matrix (ECM) remodeling by modulating the expression of matrix metalloproteinases (MMPs). MGF was associated with altered levels of various MMPs, which are involved in the degradation and remodeling of the ECM. This modulation of MMP activity may contribute to a balanced ECM environment, facilitating muscular tissue recovery and mitigating excessive fibrosis.

 

MGF and Muscle Cell Development

It is posited that MGF might support the activation and proliferation of satellite cells, which are essential for the growth and repair of muscular tissue.^[4] By potentially delaying the onset of replicative senescence, MGF may extend the proliferative lifespan of these precursor cells. This delay in senescence may be mediated through the regulation of cell cycle proteins or by modulating stress response pathways, such as the p16 pathway, which scientists believe may have some impact on cell cycle arrest. Additionally, MGF appears to promote the fusion of myoblasts into myotubes, leading to hypertrophy. This hypertrophic potential might be achieved by recruiting reserve cells—those that typically remain quiescent and undifferentiated—to participate in myotube formation. By reducing the population of reserve cells, MGF may facilitate an increase in the number of nuclei per myotube. It might even support the synthesis of contractile proteins like myosin heavy chain (MyHC). These actions suggest that MGF might play a role in optimizing the balance between cell proliferation and differentiation, thereby supporting muscular tissue maintenance and adaptation.

 

MGF and Cardiac Cell Survival

MGF has been posited to exert anti-apoptotic potential and facilitate the recruitment of stem cells, which are crucial for cardiac tissue repair.^[5] One proposed mechanism is MGF’s ability to inhibit apoptosis in cardiac myocytes. The research indicates that MGF may reduce cell death in myocytes subjected to hypoxic conditions. This protective potential appears to be associated with an increase in Bcl-2 gene expression, a protein suggested to play a role in mitigating apoptosis. The study suggests that MGF might support cell survival by modulating apoptotic pathways, potentially through the upregulation of anti-apoptotic factors like Bcl-2.

MGF is thought to be potentially involved in the recruitment and migration of stem cells to the site of cardiac cell injury. The encapsulated MGF within the microrods was observed to increase the migration of mesenchymal stem cells (hMSCs) in vitro. This chemotactic activity of MGF may create a favorable microenvironment for stem cell homing, which is essential for tissue regeneration and repair. The mechanism behind this may involve MGF interacting with the IGF-1 receptor and activating downstream signaling pathways such as Erk1/2, which are implicated in cell migration and survival.

 

MGF and Muscular Tissue Fiber Thickness

Researchers have commented that full-length MGF may have “resulted in a 25% increase in the mean muscle fiber cross-sectional area” in experimental settings.^[6] The researchers posit that full-length MGF might engage similar signaling pathways as IGF-I, which is believed to coordinate myoblast proliferation, differentiation, and fiber formation in muscular tissue. The comparable maximal activation of IGF-IR by MGF at high concentrations indicates that, under certain conditions, MGF may potentially interact with the growth of muscular tissue akin to IGF-I. Additionally, full-length MGF was found to activate the insulin receptors IR-A and IR-B. The activation of IR-A by MGF reached levels similar to those induced by insulin at high concentrations, while IR-B stimulation by MGF was even more pronounced. This dual receptor activation posits that MGF may influence multiple signaling cascades involved in hypertrophy and repair of muscular tissue. The hypothetically better-supported stimulation of IR-B suggests a possible role for MGF in modulating metabolic and growth-related pathways that contribute to increased fiber size in muscular tissue. However, the truncated version of MGF may not have a similar potential

 

MGF and Bone Cell Proliferation

In experimental models involving bone defects, MGF was apparently associated with accelerated healing, which might be attributed to its potential to promote osteoblast activity and proliferation. This accelerated healing might result from better-supported cellular processes that support bone regeneration and remodeling. The potential mechanisms by which MGF influences bone cells and tissues appear to involve several intricate cellular pathways.

Primarily, MGF is believed to support the proliferation of osteoblast-like cells, as supported by data collected by observing the cells and their hypothesized ability to increase cell growth more than IGF-1. However, the researchers also noted that the “peptide actions were independent of IGF-IR signaling,” suggesting an alternative proliferative potential. This pro-proliferative potential might be mediated through the modulation of the cell cycle, where MGF possibly induces an accumulation of cells in the S and G2/M phases. Such cell cycle alterations suggest that MGF may even facilitate DNA synthesis and promote entry into mitosis, which may hypothetically support increased cell division.

 

MGF and Cartilage Cells

Some researchers suggest that MGF might regulate chondrocyte proliferation and migration.^[7] Studies indicate that MGF may support the mobility of mesenchymal stem cells (MSCs) and chondrocytes, possibly facilitating their recruitment to injury sites. This migration may be mediated through the activation of the RhoA/Yes-associated protein (YAP) signaling pathway, which is involved in cytoskeletal reorganization and cell movement. By promoting focal adhesion formation and cytoskeleton stability, MGF may help chondrocytes navigate the damaged environment to participate in tissue repair.

Additionally, MGF may influence chondrocyte differentiation and extracellular matrix (ECM) production. In the presence of transforming growth factor-beta 3 (TGF-β3), MGF appears to accelerate the differentiation of bone marrow mesenchymal stem cells (BMSCs) into chondrocytes, potentially supporting the synthesis of type II collagen (Col2) and aggrecan, key components of the cartilage ECM. This action might be linked to the activation of the extracellular signal-regulated kinase (ERK) pathway, which is associated with cellular differentiation processes.

MGF also appears to play some kind of role in modulating inflammatory responses and apoptosis within cartilage tissue. It may reduce the expression of pro-inflammatory cytokines such as interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α), thereby potentially alleviating inflammation-induced cartilage degradation. Furthermore, MGF might inhibit apoptotic pathways by downregulating proteins like Bax and caspase-3 while upregulating Bcl-2, which may help preserve chondrocyte viability in stressful environments. The interaction of MGF with signaling pathways such as phosphoinositide 3-kinase (PI3K)/Akt and ERK/MAPK suggests it may help maintain cartilage homeostasis by promoting ECM synthesis and inhibiting catabolic processes.

The exact outcomes of these pathway activations appear to be context-dependent, varying between normal and damaged cartilage conditions. For instance, while PI3K/Akt signaling is generally associated with anabolic activities in functional cartilage, its role in damaged tissue is believed to potentially involve complex regulatory actions that are not yet fully understood. Moreover, MGF’s ability to induce the unfolded protein response (UPR) through pathways like protein kinase RNA-like ER kinase (PERK) indicates a potential role in managing cellular stress within chondrocytes. By influencing UPR-related proteins such as glucose-regulated protein 78 (GRP78), MGF may help chondrocytes adapt to hypoxic or mechanically stressful environments, thereby supporting their survival and function.

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

 

References:

1. Li C, Vu K, Hazelgrove K, Kuemmerle JF. Increased IGF-IEc expression and mechano-growth factor production in intestinal muscle of fibrostenotic Crohn’s disease and smooth muscle hypertrophy. Am J Physiol Gastrointest Liver Physiol. 2015 Dec 1;309(11):G888-99. doi: 10.1152/ajpgi.00414.2014. Epub 2015 Oct 1. PMID: 26428636; PMCID: PMC4669353.
2. Matheny RW Jr, Nindl BC, Adamo ML. Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology. 2010 Mar;151(3):865-75. doi: 10.1210/en.2009-1217. Epub 2010 Feb 3. PMID: 20130113; PMCID: PMC2840678.
3. Liu X, Zeng Z, Zhao L, Chen P, Xiao W. Impaired Skeletal Muscle Regeneration Induced by Macrophage Depletion Could Be Partly Ameliorated by MGF Injection. Front Physiol. 2019 May 17;10:601. doi: 10.3389/fphys.2019.00601. PMID: 31164836; PMCID: PMC6534059.
4. Kandalla PK, Goldspink G, Butler-Browne G, Mouly V. Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mech Ageing Dev. 2011 Apr;132(4):154-62. doi: 10.1016/j.mad.2011.02.007. Epub 2011 Feb 25. PMID: 21354439.
5. Doroudian G, Pinney J, Ayala P, Los T, Desai TA, Russell B. Sustained delivery of MGF peptide from microrods attracts stem cells and reduces apoptosis of myocytes. Biomed Microdevices. 2014 Oct;16(5):705-15. doi: 10.1007/s10544-014-9875-z. PMID: 24908137; PMCID: PMC4418932.
6. Janssen JA, Hofland LJ, Strasburger CJ, van den Dungen ES, Thevis M. Potency of Full-Length MGF to Induce Maximal Activation of the IGF-I R Is Similar to Recombinant Human IGF-I at High Equimolar Concentrations. PLoS One. 2016 Mar 18;11(3):e0150453. doi: 10.1371/journal.pone.0150453. PMID: 26991004; PMCID: PMC4798685.
7. Liu Y, Duan M, Zhang D, Xie J. The role of mechano growth factor in chondrocytes and cartilage defects: a concise review. Acta Biochim Biophys Sin (Shanghai). 2023 May 12;55(5):701-712. doi: 10.3724/abbs.2023086. PMID: 37171185; PMCID: PMC10281885.